Spondyloarthritis & psoriatic arthritis
Effectiveness of secukinumab in radiographic and non-radiographic axial spondyloarthritis: a European routine-care observational study
Main finding · Crude PRO remission, pain ≤2 (NRS 0-10)Result — go to the resultOR for achieving remission (pain ≤2) 1.7Authors' conclusion
Crude remission/drug retention rates in European secukinumab-treated patients were higher in r-axSpA compared with nr-axSpA patients. In adjusted analyses, secukinumab effectiveness was similar in both groups
Study context
- Population
- Secukinumab-treated axial spondyloarthritis (axSpA) patients with known radiographic status in routine care, nine European countries
- Participants
- 1,161 patients
- Exposure
- Secukinumab in r-axSpA vs nr-axSpA
- r-axSpAn = 922
- nr-axSpAn = 239reference
- Outcome
- PRO-based remission (pain ≤2, BASDAI ≤2) and Ankylosing Spondylitis Disease Activity Score (ASDAS) inactive disease (<1.3), and drug retention
- Follow-up
- 6/12/24 months
Methodological detailsroutine care, pooled data from nine European countries, logistic and Cox regression (unadjusted/adjusted for age+sex/adjusted for multiple confounders)
- Routine care
- Pooled data from nine European countries
- Logistic and Cox regression (unadjusted/adjusted for age+sex/adjusted for multiple confounders)
Main finding
Crude PRO remission, pain ≤2 (NRS 0-10) · 6 months
OR for achieving remission (pain ≤2)
1.7
By group
As reported in the abstract
Observational data: associations, not effects.
Further findings
Crude PRO remission, BASDAI ≤2 · 6 months · crude
OR for achieving remission (BASDAI ≤2) 1.8
Drug retention · 24 months · ref: r-axSpA, as printed; crude
HR 0.73
ASDAS inactive disease (<1.3) · 6 months
Adjusted remission and drug retention
- After adjusting for multiple confounders, no significant between-group differences remained for either remission or drug retention rates
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →